C-Path Receives BAA Award From FDA to Support ADTKD Drug Development

Critical Path Institute (C-Path) announced that its Polycystic Kidney Disease Outcomes Consortium has received a Broad Agency Announcement (BAA) contract focused on autosomal dominant tubulointerstitial kidney disease (ADTKD) from the US Food and Drug Administration (FDA).

C-Path is an independent nonprofit whose mission is to lead collaborations that advance better treatments worldwide. The organization has established numerous international consortia, programs, and initiatives including more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations, and pharmaceutical and biotech companies.

The BAA award will support C-Path’s work in collaboration with the Wake Forest Rare Inherited Kidney Disease team and its ADTKD registry, to analyze clinical and laboratory data that will help assess prognosis in ADTKD and advance future drug development efforts and clinical trials.

ADTKD is primarily caused by genetic mutations in the UMOD and MUC1 genes. Because it is rare and was only recently identified as a cause of kidney disease, little is known about factors that affect progression of kidney disease in ADTKD. Identification of the genetic causes of ADTKD has led to increased detection, and it is now estimated to be the third most common form of inherited kidney disease.